131 related articles for article (PubMed ID: 25802907)
1. Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
Herishanu Y; Katz BZ
Blood; 2015 Feb; 125(6):1047. PubMed ID: 25802907
[No Abstract] [Full Text] [Related]
2. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Tsutsumi Y; Ogasawara R; Miyashita N; Tanaka J; Asaka M; Imamura M
Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099
[No Abstract] [Full Text] [Related]
3. Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma.
Sadashiv SK; Rao R; Fazal S; Lister J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):602-5. PubMed ID: 23870855
[No Abstract] [Full Text] [Related]
4. Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab.
Warsch S; Hosein PJ; Morris MI; Teomete U; Benveniste R; Chapman JR; Lossos IS
Int J Hematol; 2012 Aug; 96(2):274-8. PubMed ID: 22684926
[TBL] [Abstract][Full Text] [Related]
5. [Recommendation for the optimal use of bendamustine in Japan].
Ohmachi K; Maruyama D; Nisikori M; Suzuki T; Izutsu K
Rinsho Ketsueki; 2014 Mar; 55(3):311-20. PubMed ID: 24681934
[No Abstract] [Full Text] [Related]
6. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report.
Gueli A; Gottardi D; Hu H; Ricca I; De Crescenzo A; Tarella C
Blood Transfus; 2013 Apr; 11(2):311-4. PubMed ID: 23399352
[No Abstract] [Full Text] [Related]
7. CCMCL1: a new model of aggressive mantle cell lymphoma.
Zhao X; Chen-Kiang S; Shetty S; Di Liberto M; Bodo J; Durkin L; Eng K; Elemento O; Smith MR; Hsi ED
Blood; 2015 Apr; 125(17):2730-2. PubMed ID: 25907904
[No Abstract] [Full Text] [Related]
8. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Rummel MJ; Mitrou PS; Hoelzer D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Prescrire Int; 2016 Apr; 25(170):91. PubMed ID: 27186618
[No Abstract] [Full Text] [Related]
13. Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
Hagiwara K; Tokunaga T; Iida H; Nagai H
Anticancer Res; 2015 Dec; 35(12):6679-84. PubMed ID: 26637884
[TBL] [Abstract][Full Text] [Related]
14. Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
Hui M; Chen M
Ann Hematol; 2022 Apr; 101(4):911-913. PubMed ID: 34487230
[No Abstract] [Full Text] [Related]
15. Ibrutinib for the treatment of mantle cell lymphoma.
Shah N; Hutchinson C; Rule S
Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606
[TBL] [Abstract][Full Text] [Related]
16. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.
Dietrich S; Weidle J; Rieger M; Meissner J; Radujkovic A; Ho AD; Dreger P; Witzens-Harig M
Leukemia; 2014 Mar; 28(3):708-9. PubMed ID: 24217198
[No Abstract] [Full Text] [Related]
17. Bendamustine: more ammunition in the battle against mantle cell lymphoma.
Chang JE; Kahl BS
Leuk Lymphoma; 2012 Jul; 53(7):1249-50. PubMed ID: 22220986
[No Abstract] [Full Text] [Related]
18. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
19. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Romaguera JE; Lee HJ; Tarapore R; Prabhu V; Allen J; Schalop L; Zloza A; Ok CY; Sadimin ET; Schenkel J; Badillo M; Wang M
Br J Haematol; 2019 Apr; 185(1):133-136. PubMed ID: 29740811
[No Abstract] [Full Text] [Related]
20. Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.
Mori S; Patel RD; Ahmad S; Varela J; Smith T; Altoos R; Shen Q; Goldstein SC; Persky DO
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):e93-e97. PubMed ID: 30559058
[No Abstract] [Full Text] [Related]
[Next] [New Search]